Mucofluid (Mesna)

• Mesna is employed as a chemoprotective adjuvant in oncology protocols to mitigate the urotoxic effects of certain alkylating chemotherapeutic agents, primarily cyclophosphamide and ifosfamide.
• Hemorrhagic cystitis: prevents bladder inflammation, bleeding, dysuria, and associated urinary symptoms that can arise during cyclophosphamide or ifosfamide chemotherapy, thereby preserving patient quality of life.
• Urotoxicity prevention: diminishes overall urinary tract toxicity, reduces risk of renal impairment, and supports renal function during high‑dose cyclophosphamide or ifosfamide treatment courses.
• Adjunctive therapy: administered alongside adequate hydration and diuresis protocols to further lower the incidence and severity of bladder toxicity in patients receiving cyclophosphamide or ifosfamide.

• Mesna provides free sulfhydryl groups that chemically bind the toxic metabolite acrolein produced during cyclophosphamide and ifosfamide metabolism. This conjugation forms a non‑reactive complex that is excreted in the urine, thereby preventing acrolein‑induced damage to the urothelium and reducing the incidence of hemorrhagic cystitis.

Mesna may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects

• Nausea: mild to moderate discomfort in the stomach.
• Vomiting: occasional episodes, usually self‑limited.
• Headache: transient and mild.
• Rash: localized skin irritation or erythema.
• Mild hypotension: temporary drop in blood pressure without severe symptoms.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergy requiring immediate medical attention.
• Pulmonary edema: fluid accumulation in the lungs, presenting with shortness of breath.
• Hemolysis: destruction of red blood cells leading to anemia.
• Severe hypotension: marked blood pressure reduction causing dizziness or fainting.
• Renal failure: impaired kidney function requiring monitoring.

When using Mesna, clinicians should consider several safety measures to minimize risk.

• Renal function monitoring: assess baseline and periodic creatinine levels.
• Hypersensitivity assessment: discontinue if signs of allergic reaction appear.
• Dose adjustment: modify in patients with existing renal impairment.
• Concomitant urotoxic agents: avoid or closely monitor use with other nephrotoxic drugs.
• Adequate hydration: ensure patients receive sufficient fluid intake during therapy.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mesna can interact with other medicines, influencing its protective effect or increasing toxicity.

Major Interactions (Avoid)

• Nephrotoxic drugs (e.g., aminoglycosides): may amplify renal injury.
• Other sulfhydryl donors (e.g., N‑acetylcysteine): can interfere with acrolein binding.
• Strong oxidizing agents (e.g., hydrogen peroxide solutions): may reduce Mesna's efficacy.

Moderate Interactions (Monitor Closely)

• Loop diuretics: monitor electrolytes and fluid balance.
• Antihypertensives: observe blood pressure for additive hypotensive effects.